Equities
  • Price (MXN)3,625.00
  • Today's Change0.00 / 0.00%
  • Shares traded1.00
  • 1 Year change--
  • Beta--
Data delayed at least 20 minutes, as of Nov 04 2024 18:51 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

AMETEK, Inc. is a global provider of industrial technology solutions serving a diverse set of niche markets. The Company’s segments include Electronic Instruments (EIG) and Electromechanical (EMG). The EIG segment manufactures advanced instruments for the process, power and industrial, and aerospace markets. It provides process and analytical instruments for the oil and gas, petrochemical, pharmaceutical, semiconductor, automation, and food and beverage industries. The EIG segment also provides instruments to the laboratory equipment, ultra-precision manufacturing, medical, and test and measurement markets. The EMG segment designs and manufactures engineered medical components and devices, automation solutions, thermal management systems, specialty metals and electrical interconnects. The Company’s EMG segment makes precision motion control products for data storage, medical devices, business equipment, automation, and other applications.

  • Revenue in USD (TTM)6.91bn
  • Net income in USD1.33bn
  • Incorporated1986
  • Employees21.50k
  • Location
    AMETEK Inc1100 Cassatt RoadBERWYN 19312United StatesUSA
  • Phone+1 (610) 647-2121
  • Fax+1 (215) 323-9337
  • Websitehttps://www.ametek.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
AME:NYQ since
announced
Transaction
value
Jack Nathan Medical Corp-Canadian Clinical AssetsAnnounced04 Nov 202404 Nov 2024Announced7.00%3.58m
Virtek Vision International IncDeal completed31 Oct 202431 Oct 2024Deal completed13.03%--
Data delayed at least 15 minutes, as of Nov 09 2024.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.